Gilead Sciences Profile

USD 1.70  2.36%

Sale by Gregg Alton of 2100 shares of Gilead Sciences

Gilead Sciences insider trading alert for sale of common stock by Gregg Alton, SVP General Counsel, on September 19, 2018. This event was filed by Gilead Sciences Inc with SEC on 2008-01-04. Statement of changes in beneficial ownership - SEC Form 4. Gregg Alton is currently serves as executive vp of corporate and medical affairs and secretary of Gilead Sciences [view details]   

Gilead Sciences Summary

Gilead Sciences made a $10 billion bet and lost.? They invested heavily into a drug that was denied release by the FDA.? Naturally, the stock was sold off sharply.? While the stock was sitting at highs of nearly $50.00, it is now a mere 10% of the level now.? But, just because the stock is beaten down as it is, does that mean it is a bad bet? ? [more]
Gilead Sciences (GILD) is traded on BATS Exchange in USA. It is located in CALIFORNIA U.S.A and employs 10,000 people. Gilead Sciences is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Large-Cap' category with current market capitalization of 95.57 B. Gilead Sciences conducts business under Healthcare sector and is part of Biotechnology industry. This company has 1.3 B outstanding shares of which 13.98 M shares are currently shorted by private and institutional investors with about 2.23 trading days to cover. GILEAD SCIENCES currently holds about 27.1 B in cash with 8.31 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 20.91.
Check Gilead Sciences Probability Of Bankruptcy

Ownership Allocation (%)

Gilead Sciences Target Price Odds Analysis

Odds Below 73.88HorizonTargetOdds Above 73.88
54.99%30 days 73.88 44.38%
Based on normal probability distribution, the odds of Gilead Sciences to move above current price in 30 days from now is about 44.38% (This Gilead Sciences probability density function shows the probability of Gilead Sciences Stock to fall within a particular range of prices over 30 days) .

Gilead Sciences Top Holders

Gilead Sciences Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Blackrock IncCommon Shares105.2 M7.5 B
Vanguard Group IncCommon Shares96.1 M6.8 B
View Gilead Sciences Diagnostics

Gilead Sciences Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Gilead Sciences Key Fundamentals

Gilead Sciences Against Markets

Gilead Sciences Current Ratings

Gilead Sciences 30 Days Performance Scores

Risk Adjusted
Performance Score (0 to 100)
Chance of
Financial Distress (0 to 100%)
Equity ratings for Gilead Sciences are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company was founded in 1987 and is headquartered in Foster City, California. Gilead Sciences operates under Biotechnology classification in USA and traded on BATS Exchange. It employs 10000 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Gilead Sciences SEC Filings
Gilead Sciences SEC Filings
Security & Exchange Commission EDGAR ReportsView All
NameGilead Sciences
Chairman and CEOJohn MartinView All
Thematic Classifications
Active Investing Ideas
Analyst Consensus
Piotroski F Score
Macroaxis Advice
Bond Rating
Healthcare, Biotechnology
InstrumentUSA Stock View All
RegionNorth America
Business Address333 Lakeside Drive
Foreign Associates
ExchangeBATS Exchange
CIK Number0000882095
Phone650 574 3000
CurrencyUSD - US Dollar
Next Fiscal Year EndDecember 31, 2019
Most Recent QuarterJune 30, 2018
Last Fiscal Year EndDecember 31, 2017
Date Short InterestAugust 15, 2018

Did you try this?

Run Equity Search Now


Equity Search

Search for activelly-traded equities including funds and ETFs from over 30 global markets
All  Next Launch Equity Search

Gilead Sciences Dividends

Upcoming distributions to stockholders

Gilead Sciences Directors

Gilead Sciences Corporate Directors

Gayle Wilson Independent Director
Jacqueline Barton Director
John Madigan Independent Director
Please also check Risk vs Return Analysis. Please also try Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.